The Most Prestigious Researchers In The World Are Interested In The Results Obtained By The Spanish Dermatologist Of Palestinian Origin, Dr Azmi Mohammad Mustafa, Pioneer In The Treatment Of Vitiligo Using Polypodium Leucotomos Extract, New Hope For Sufferers From This Malady.
CAUSES OF VITILIGO:
Melanin is the pigment that gives the skin its characteristic color. Vitiligo is caused by a loss of pigment in the skin, due to destruction of pigment-forming cells known as melanocytes. The exact cause of the destruction of these cells is not known. One possible explanation might be that the body’s immune system destroys the cells, as in other autoimmune conditions. Although vitiligo affects all races equally, it is more noticeable in dark-skinned people.
RISK FACTORS FOR VITILIGO:
Vitiligo affects up to 2% of the population, and it is estimated that two to five million Americans have the condition. In most cases, vitiligo develops early in life, between the ages of 10 and 30 years. Ninety-five percent of those affected will develop the disorder before age 40. Both men and women are equally likely to develop vitiligo. Vitiligo may run in families; those with a family history of vitiligo or premature graying of the hair are at increased risk for the development of vitiligo. Other risk factors that increase one’s chances of developing vitiligo include having autoimmune diseases, such as autoimmune thyroid disease (Hashimoto’s thyroiditis).
SYMPTOMS OF VITILIGO
Symptoms of vitiligo include an often rapid pigment loss on several areas of the skin. The initial appearance of the white patches can be followed by a stable period without any progression of the condition. Later on, further cycles of pigment loss and stability may be observed. Vitiligo commonly affects areas on the skin that are exposed to sun, body folds (such as armpits), previous sites of injury, areas around moles, or areas around body openings. It is rare for pigment to return once the white patches have developed. Vitiligo can also affect the eyelids and hair.